Doctronic logo spinning
Skipping wait room
AI Doctor ready
Starting secure consult

Can We Treat Scleroderma? Exploring the Latest Treatment Options

Published: May 05, 2024

Treating scleroderma is challenging due to its complex nature and varying symptoms. This article explores the latest treatment options and strategies.
Contents

Initial Treatment Strategies

For patients with progressive and diffuse skin involvement, treatments like methotrexate (MTX) or mycophenolate mofetil (MMF) are commonly used. These medications are often initiated early to slow disease progression. The choice between MTX and MMF depends on other symptoms present, such as arthritis or lung involvement, as neither shows clear superiority.

Advanced and Resistant Cases

For scleroderma cases resistant to initial treatments, intravenous immunoglobulin (IVIG), rituximab, or tocilizumab may be considered. These treatments are reserved for severe cases due to their potential side effects. Cyclophosphamide is also an option for rapidly progressing skin thickening but is typically reserved for severe cases.
Scleroderma is a complex autoimmune disease characterized by skin thickening and varying symptoms. Treatment includes drugs like methotrexate and mycophenolate mofetil, with advanced options for resistant cases.

Managing Other Symptoms

Patients often experience symptoms like pruritus, which can be managed with topical treatments and antihistamines. For severe itching, short courses of low-dose glucocorticoids may be used cautiously due to potential renal risks. Other skin manifestations, such as calcinosis cutis, may require treatments like minocycline or even surgery.

Frequently Asked Questions

Methotrexate or mycophenolate mofetil is often used first.

IVIG, rituximab, or tocilizumab may be considered.

Topical treatments and antihistamines are used.

Yes, especially for calcinosis cutis if other treatments fail.

They can increase the risk of renal crisis in scleroderma.

Wrapping Up

While no cure exists, several treatment options can effectively manage scleroderma symptoms.
Try discussing these treatment options with Doctronic to see what might work for you.

Related Articles

References

  1. Nihtyanova SI, Sari A, Harvey JC, et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. Arthritis Rheumatol 2020; 72:465.

This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic. Always discuss health information with your healthcare provider.

AI Doctor Visit Required

Appointments available 24/7

😀 😀 😀
sthetoscope

Top licensed doctors

Available in all 50 states

dossier

Full service care

Prescriptions, referrals & treatment

check

No insurance needed

All notes available in Doctronic

15-min consultation. No hidden costs.

AI Doctor Visit Required
Close icon

Please Chat With Our AI Doctor First

Our AI doctor assessment helps our human doctors prepare for your video visit and provide better care

Lifebuoy

For safety reasons we have been forced to end this consultation.

If you believe this is a medical emergency please call 911 or your local emergency services immediately.

If you are experiencing emotional distress, please call the the Suicide & Crisis Lifeline at 988 or your local crisis services immediately.

Contact us

You can also email us at help@doctronic.ai

We aim to reply within 5-7 days

How likely are you to recommend Doctronic to friends or family?
Not likely at all Extremely likely